Rakan Radi

Rakan Radi

Auto-generated profile, based on publicly available information

Rakan Radi

Department of Dermatology, Emory University School of Medicine, Atlanta, GA 30322, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2023 in Cells
Verified
Journal Article
Open access
PDF file
PBPaola Baker
Paola Baker
CHChristina Huang
Christina Huang
RRRakan Radi
Rakan Radi
SMSamara B. Moll
Samara B. Moll
EJEmmanuela Jules
Emmanuela Jules
Jack ArbiserJack Arbiser
Jack Arbiser
An intact barrier function of the skin is important in maintaining skin health. The regulation of the skin barrier depends on a multitude of molecular and immunological signaling pathways. By examining the regulation of a healthy skin barrier, including maintenance of the acid mantle and appropriate levels of ceramides, dermatologists can better formulate solutions to address issues that are related to a disrupted skin barrier. Conversely, by understanding specific skin barrier disruptions that are associated with specific conditions, such as atopic dermatitis or psoriasis, the development of new compounds could target signaling pathways to provide more effective relief for patients. We aim to review key factors mediating skin barrier regulation and inflammation, including skin acidity, interleukins, nuclear factor kappa B, and sirtuin 3. Furthermore, we will discuss current and emerging treatment options for skin barrier conditions.

19 April 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
RRRakan Radi
Rakan Radi
CHChristina Huang
Christina Huang
JEJustin Elsey
Justin Elsey
YJYoon H. Jung
Yoon H. Jung
Victor G CorcesVictor G Corces
Victor G Corces
Jack ArbiserJack Arbiser
Jack Arbiser
The development of targeted therapies (BRAF/MEK inhibitors) and immunotherapy have had a major impact on the treatment of melanoma. However, the majority of patients with advanced melanomas succumb to their disease. The mechanisms of resistance to both targeted therapies and immunotherapies are numerous and have been well-described. These include the alternative activation of BRAF/MEK signaling, novel compensating mutations in additional oncogenes, and loss of neoantigens. There has been limited development of small molecules that target alternative pathways in melanoma in the last two decades. We have previously identified triphenylmethanes as a class that shows activity against a wide variety of tumors. We have synthesized a novel triphenylmethane, indolium 1, and demonstrated its efficacy against an aggressive vemurafenib-resistant melanoma in vivo. Indolium 1 has a novel mechanism of action against melanoma, in that it results in induction of the tumor-suppressor EPHA3. We believe that pre-IND studies are warranted for this novel compound, given its mechanism of action and ability to inhibit the growth of vemurafenib resistant melanoma in vivo.